Saruparib is a first-in-class PARP1 inhibitor with exquisite PARP1 selectivity that is being tested in the phase 1/2a PETRA trial in pretreated solid tumors, including prostate cancer, with a BRCA, RAD51, or ATM mutation. This evidence concerns the gene RAD51 and Familial prostate cancer.